Reuters logo
BRIEF-Human Longevity says agreement with Merck KGaA, Darmstadt, Germany to engage in cancer biomarker discovery in advanced melanoma
June 15, 2017 / 6:51 PM / in 4 months

BRIEF-Human Longevity says agreement with Merck KGaA, Darmstadt, Germany to engage in cancer biomarker discovery in advanced melanoma

June 15 (Reuters) - Human longevity Inc :

* Human longevity - signed agreement with merck kgaa, darmstadt, germany which operates its biopharmaceutical business as emd serono in u.s. And canada

* Human longevity - as part of deal, co’s have started joint pilot project to identify treatment response biomarker signatures in patients with advanced melanoma

* Human longevity inc says financial terms of deal were not disclosed Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below